Biotechnology

89Bio

Seedhouse Analyst Covers Healthcare Sector, Focusing on Multiple Stocks

Roche Completes Acquisition of Approximately 60.49% Shares of 89bio

Roche Reports Quarterly Revenue Drop and Acquires 89bio to Strengthen Position in Metabolic Diseases

Roche Plans to Acquire 89bio for up to $3.5 Billion

89bio shareholders to gain up to $3.5 billion through Roche acquisition deal

Roche Acquires 89bio for $2.4 Billion to Obtain Potential MASH Blockbuster Drug

Roche Holding Announces Acquisition of 89bio at a 79% Premium

Roche Holding AG to Acquire 89bio Inc. for $3.5 Billion

Charles Schwab Increased Its Holding in 89BIO by 21.6%

89Bio released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7062 (forecast USD -0.5006)

89Bio released FY2025 Semi-Annual earnings on August 8 (EST), actual revenue USD 0, actual EPS USD -1.2012

89bio Q2 Loss Greater Than Expected

89Bio Inc. official Quoc Le-Nguyen disposed of company stocks

Weiss Ratings Reiterates Sell Rating on 89BIO

89Bio Grants 61,100 Non-Qualified Stock Options to Employees

89bio Receives Consensus Buy Recommendation from Brokers

89bio's stock price falls with insider 减持

BofA Global Research Downgrades 89BIO INC Target Price

89BIO sees 17% increase in price

89Bio Inc. Grants Incentive Stock Options to Seven New Employees

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

ARKG

ETNB

4basebio Leases New Cambridge Facility to Scale Synthetic DNA Manufacturing

Tip Ranks

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

BioAge Labs

SPDR S&P Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Biolife4d Corp

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

4basebio Leases New Cambridge Facility to Scale Synthetic DNA Manufacturing

ABBV

Eli Lilly, Pfizer, Novo Nordisk, 89BIO, McKesson, AbbVie, and Teva Pharmaceutical Industries are highlighted as top pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in the research, development, and sale of pharmaceuticals, offering growth potential but also facing risks from clinical trials and regulatory changes. Eli Lilly recently reported strong Q3 results, indicating long-term upside. Investors are advised to consider these stocks for potential investment opportunities.

Market Beat

Novo Nordisk AS

Eli Lilly

Abbvie

Top Pharmaceutical Stocks To Add to Your Watchlist - November 6th

Eli Lilly, Pfizer, Novo Nordisk, 89BIO, and Metsera are highlighted as promising pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in developing and marketing drugs and therapies, with their stock performance influenced by clinical trials and regulatory approvals. Eli Lilly has shown strong Q3 results, while Pfizer continues to expand its biopharmaceutical offerings. Novo Nordisk focuses on diabetes and obesity care, 89BIO targets liver diseases, and Metsera develops treatments for obesity. Investors are advised to monitor these stocks closely for potential opportunities.

- Eli Lilly and Company, along with Pfizer, Novo Nordisk, 89BIO, and Metsera, are highlighted as key pharmaceutical stocks to monitor due to their recent high trading volumes.  
- The pharmaceutical sector is influenced by factors such as clinical trial outcomes, regulatory approvals, and pricing pressures, which can lead to significant volatility and investment opportunities.  
- Despite a Moderate Buy rating for Eli Lilly, analysts suggest that there are currently five other stocks that may present better investment prospects.

Pfizer

Promising Pharmaceutical Stocks Worth Watching - November 4th

Cantor Fitzgerald has reiterated an "overweight" rating on 89BIO (NASDAQ:ETNB) shares. Other analysts have mixed views, with Weiss Ratings giving a "sell (d-)" rating, Wolfe Research downgrading to "peer perform," and Zacks lowering to "strong sell." The stock remains flat at $14.84, with a consensus rating of "Hold" and a target price of $25.81. 89BIO reported a quarterly EPS of ($0.71), missing estimates. The company focuses on therapies for liver and cardio-metabolic diseases, with a market cap of $2.20 billion.

89BIO (NASDAQ:ETNB) Receives "Overweight" Rating from Cantor Fitzgerald

According to TipRanks, Seedhouse is a 4-star analyst with an average return of 11.5% and a 44.69% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Astria Therapeutics, BioCryst, and Tvardi Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 89bio with a $30.19 average price target.

Cantor Fitzgerald Remains a Buy on 89bio (ETNB)

89bio has completed its merger, resulting in its delisting from Nasdaq and significant changes in its management structure. The company is now a wholly owned subsidiary of its parent company, with board members resigning. The latest analyst rating for ETNB stock is a Hold with a $14.50 price target. Spark's AI Analyst rates ETNB as Neutral, citing ongoing losses and cash flow issues, despite promising clinical progress. The stock is considered high-risk, high-reward, with a current market cap of $2.2B and an average trading volume of 5,392,262 shares.

89bio Completes Merger and Delists from Nasdaq

On October 27, 2025, 89bio, Inc. announced changes to its board and executive team following a merger. Dara Pincas and Roger Brown were appointed as directors, while several directors, including Rohan Palekar and Steven M. Altschuler, resigned. The changes are effective immediately and are part of the merger agreement. The details of the resignations and replacements were not disclosed.

TradingView

89bio, Inc. Announces Board and Officer Changes Following Merger

RHHBY

Basel, 30 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common ...

GlobeNewswire

Roche

Roche purchases shares in tender offer for 89bio, Inc

89Bio(ETNB.US)

4basebio Leases New Cambridge Facility to Scale Synthetic DNA Manufacturing

Top Pharmaceutical Stocks To Add to Your Watchlist - November 6th

Promising Pharmaceutical Stocks Worth Watching - November 4th

89BIO (NASDAQ:ETNB) Receives "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald Remains a Buy on 89bio (ETNB)

89bio Completes Merger and Delists from Nasdaq

89bio, Inc. Announces Board and Officer Changes Following Merger

Roche purchases shares in tender offer for 89bio, Inc